-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson's Tremfya reduces axial psoriatic arthritis symptoms in Phase 4 trial

PUBT·11/20/2026 13:01:53
Listen to the news
Johnson & Johnson's Tremfya reduces axial psoriatic arthritis symptoms in Phase 4 trial
  • Johnson & Johnson's Tremfya met key endpoints in the Phase 4 STAR trial in adults with psoriatic arthritis involving the spine.
  • Treatment significantly improved axial symptoms versus placebo, with MRI scans confirming reduced sacroiliac joint inflammation.
  • No new safety signals emerged; findings supported Tremfya's established safety profile.
  • Late-breaking results are being presented at the Emirates Society for Rheumatology Annual Meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611200800PR_NEWS_USPR_____NY02933) on November 20, 2026, and is solely responsible for the information contained therein.